Sovaldi In Medicaid: Contractor Molina Urges Government To Assume Up-Front Cost
Executive Summary
Medicaid managed care organization Molina says its 2014 payment rates are not adequate to cover the cost of Gilead Sciences’ hepatitis C drug Sovaldi and that the government should handle the upfront costs. WellPoint’s Medicaid plans have seen a 50% increase in the cost of treating hepatitis C patients.
You may also be interested in...
Medicaid Coverage For Gilead’s Sovaldi “Imprudent” Unless Price Reduced – Patient Group
In response to price concerns with Sovaldi, Gilead Sciences emphasized that “Medicaid, by law, receives very deep discounts, and Gilead is working with each state to complete the necessary steps to ensure a timely review and addition to the state formulary.”
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.